Wall Street Bullish Sentiment Grows for Bristol Myers Squibb

Yahoo Finance · 2026-09-20

Shares of Bristol Myers Squibb have advanced a little more than 17% year-to-date. Although analysts project an average price target of $66.71, sitting just slightly above its present trading value, rising momentum in the firm's expansion portfolio helps offset worries surrounding upcoming patent cliffs for major blockbusters like Eliquis and Opdivo. The healthcare giant delivered robust second-quarter financial results, posting revenues of $12.9 billion—a 6% year-over-year increase—alongside earnings per share of $1.62, surging 153% compared to the prior year. Despite this impressive operational execution, the equity remains attractively priced at under 10 times forward earnings and less than 14 times trailing earnings. This valuation represents a discount relative to most mega-cap pharmaceutical competitors such as AbbVie, AstraZeneca, Merck, Johnson & Johnson, Pfizer, and Roche, reinforcing the strengthening bullish narrative.

AI 시장 분석

Bristol-Myers Squibb (BMY) has risen over 17% this year, reporting Q2 revenue of $12.9 billion (a 6% increase year-over-year) and earnings per share (EPS) of $1.62 (a 153% increase). Despite concerns over patent expirations for key products, Wall Street's bullishness is gaining momentum, highlighted by a strong growth portfolio and a low forward price-to-earnings ratio (P/E) of under 10x. Investors should take note of its attractive valuation and strong performance compared to major pharmaceutical peers.

상승 영향

Biotechnology — Bristol-Myers Squibb achieved strong Q2 performance with revenue of $12.9 billion and EPS of $1.62, highlighting its undervalued appeal with a forward P/E of under 10x, which could improve investment sentiment across the pharmaceutical sector.

하락 영향

Biotechnology — As patent expirations for flagship products like Eliquis and Opdivo loom near, lingering concerns over future revenue gaps and intensified generic competition may act as a burden on stock price appreciation.

DYAX 전담 분석

Bristol-Myers Squibb achieved better-than-expected results in Q2 with revenue of $12.9 billion and EPS of $1.62. Although concerns regarding the patent expirations of Eliquis and Opdivo are already priced into the stock, the undervalued appeal with a forward P/E of under 10x and a growth portfolio centered on new products are offsetting these risks.

In the bullish scenario, sales from new drugs could quickly fill the patent expiration gap, and valuations could converge toward the average of large-cap pharmaceutical companies. In the bearish scenario, intensifying generic competition for key products could make it difficult to defend profitability, so future pipeline revenue share and earnings trends must be monitored as core indicators.

AI가 생성한 분석으로 투자 자문이 아닙니다.

DYAX Investor Sentiment

Bullish (Long) 44% · Bearish (Short) 56%

459 participants

Related News

원문 보기 — Yahoo Finance